Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis [Yahoo! Finance]
Cabaletta Bio, Inc. (CABA)
Company Research
Source: Yahoo! Finance
internal organ fibrosis, face limited treatment options as current therapies provide only modest effects and focus on treating the complications associated with the disease. With an average patient survival of 12 years following diagnosis, there is a significant unmet need for new treatment options that focus on eliminating the root cause of the disease to prevent further organ damage for patients,” said David J. Chang, M.D., Chief Medical Officer of Cabaletta. “Based on the role of B cells and the recently published academic clinical data with CD19-CAR T therapy in systemic sclerosis, we believe CABA-201 may transform the treatment for systemic sclerosis. Orphan Drug Designation is an important recognition for investigational therapies for rare diseases and provides us with potentially valuable benefits as we develop CABA-201 for patients with systemic sclerosis.” The FDA grants Orphan Drug Designation to drugs or biologics intended to treat or prevent rare diseases or conditions t
Show less
Read more
Impact Snapshot
Event Time:
CABA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CABA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CABA alerts
High impacting Cabaletta Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CABA
News
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.MarketBeat
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Citigroup Inc. from $26.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.MarketBeat
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at Wells Fargo & Company from $34.00 to $35.00. They now have an "overweight" rating on the stock.MarketBeat
- Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target raised by analysts at HC Wainwright from $25.00 to $30.00. They now have a "buy" rating on the stock.MarketBeat
CABA
Earnings
- 3/21/24 - Miss
CABA
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- CABA's page on the SEC website